Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin 2 toxin: a step toward selective immunomodulation.

J R Murphy1, V E Kelley, T B Strom

  • 1Evans Department of Clinical Research, University Hospital, Boston University Medical Center, MA 02118.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|February 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigation of Localized Skin Temperature Distribution Across the Transtibial Residual Limb.

Canadian prosthetics & orthotics journal·2023
Same author

Forkhead box protein 3(+) regulatory T cells and Helios(+) subset in perinatally acquired HIV.

Clinical and experimental immunology·2014
Same author

Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity.

Science (New York, N.Y.)·2011
Same author

The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia.

BJOG : an international journal of obstetrics and gynaecology·2010
Same author

Trojan horse or proton force: finding the right partner(s) for toxin translocation.

Neurotoxicity research·2006
Same author

An investigation into the structure and bioavailability of alpha-tocopherol dispersions in Gelucire 44/14.

Journal of controlled release : official journal of the Controlled Release Society·2003
Same journal

Approach to Hyperkalemia: The Role of Diet and Pharmacological Therapies.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

High Protein Diets: What to Tell Our Patients.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Progressive Kidney Dysfunction and Ocular Clues: A Quiz.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Influence of Lactate Dehydrogenase on the Measurement of Blood Bicarbonate.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Urinary CXCL9 and CXCL10, Interstitial Inflammation and Disease Activity Over Time in Acute Interstitial Nephritis.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Hemophagocytic Lymphohistiocytosis and Fibroblast Growth Factor 23 (FGF23)-Induced Hypophosphatemia.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
See all related articles

Researchers engineered a novel IL-2 toxin by combining diphtheria toxin and interleukin 2 (IL-2). This hybrid selectively targets and inhibits protein synthesis in T cells expressing IL-2 receptors, demonstrating potent immunosuppressive effects in vivo.

Area of Science:

  • Biotechnology
  • Immunology
  • Molecular Biology

Background:

  • Diphtheria toxin is a potent cytotoxin.
  • Interleukin 2 (IL-2) is a key cytokine for T cell growth and function.
  • Targeted delivery of cytotoxic agents to specific cell types is a goal in therapeutic development.

Purpose of the Study:

  • To create a fusion protein combining diphtheria toxin and IL-2.
  • To investigate the selective cytotoxicity of the fusion protein on T cells.
  • To evaluate the immunosuppressive potential of the engineered toxin.

Main Methods:

  • Protein engineering and recombinant DNA techniques were used.
  • The receptor binding domain of diphtheria toxin was replaced with IL-2.
  • The fusion gene was cloned and expressed in Escherichia coli.

Related Experiment Videos

  • Cytotoxicity assays were performed on human and murine T cell lines.
  • In vivo studies utilized a murine delayed type hypersensitivity (DTH) model.

    • Main Results:

    • A 68,086 K hybrid toxin, termed IL-2 toxin, was produced.
    • IL-2 toxin selectively inhibited protein synthesis in T cells bearing high-affinity IL-2 receptors.
    • Cytotoxicity was blocked by free IL-2 and antibodies against the IL-2 receptor's p55 subunit.
    • The toxin requires an acidic compartment for intracellular delivery of its enzymatic activity.
    • IL-2 toxin induced significant immunosuppression in a murine DTH model.

    Conclusions:

    • The engineered IL-2 toxin demonstrates specific targeting and cytotoxic activity against IL-2 receptor-bearing T cells.
    • This targeted approach offers potential for developing novel immunomodulatory therapies.
    • The mechanism of action involves specific receptor binding and intracellular delivery, similar to native diphtheria toxin.